Presently, there is no efficacious treatment for glaucomatous optic neuropathy; the current
treatment is focused on lowering intraocular pressure (IOP). Studies have demonstrated the …

Glaucoma is the leading cause of irreversible blindness worldwide. As a chronic disease,
glaucoma presents a significant burden to the individual, health‐care provider and the …

Purpose Selective laser trabeculoplasty (SLT) is a common treatment option for managing
glaucoma and ocular hypertension. We assessed the real-world effectiveness of SLT and …

PURPOSE: The LiGHT trial has shown selective laser trabeculoplasty (SLT) to be clinically
and cost-effective as a primary treatment of open-angle glaucoma (OAG) and ocular …

Purpose To compare visual field outcomes of ocular hypertensive and glaucoma patients
treated first with medical therapy with those treated first with selective laser trabeculoplasty …

Glaucoma is a chronic, debilitating disease and a leading cause of global blindness.
Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US,> 80% of …

Purpose To determine the efficacy of repeat selective laser trabeculoplasty (SLT) in
medication-naive open-angle glaucoma (OAG) and ocular hypertensive (OHT) patients …

Purpose The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown
selective laser trabeculoplasty (SLT) to be clinically and cost-effective as a primary treatment …

Abstract The recent Laser in Glaucoma and Ocular Hypertension Trial provided the
evidentiary basis for a paradigm shift away from the historical medication-first approach to …

Purpose: To determine the association of statins, five classes of antihypertensive
medications, and proton pump inhibitors with (1) primary open-angle glaucoma (POAG) …